<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">A new governance model was called for to accelerate global health innovation and impact, where private and public partners are aligned in a manner that proactively defines roles and responsibilities, specifies key data needed for future policy decisions, secures procurement and implementation, and shares risks in a reasonable manner. The overarching challenges for the private industry are the limited return on investment for many vaccines against poverty diseases, the opportunity cost, 
 <italic>i.e.,</italic> money taken from other development projects, inconsistent resourcing due to shifting global attention or disease prevalence, and scientific complexity of many “remaining” pathogens, 
 <italic>e.g.,</italic> HIV, which continues to be a disaster in the human population. There are examples of private industry companies that despite lack of commercial opportunity decided to support the development of an Ebola vaccine.
</p>
